Saturday 17 October 2026
Export SGMT’s income statement to Excel — free account
Sagimet Biosciences Inc.
SGMT Healthcare Biotechnology
Sagimet Biosciences Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.0 million. In the quarter to June 2026, EPS grew 18.8% and free cash flow fell 22.0%, each against the same quarter a year earlier.
8.02
0.15
−1.84%
Follow SGMT
Sagimet Biosciences Inc. (SGMT) P/E ratio
Sagimet Biosciences Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.2× (May 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2023 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.2×
Ten-year median
0.0×
Current reading's percentile
77
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| STTK Shattuck Labs, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| DBVT DBV Technologies S.A. compare | n/m |
| VECT VectivBio Holding AG compare | n/m |
| SGMT Sagimet Biosciences Inc. | n/m |
| SLN Silence Therapeutics PLC Sponsored ADR compare | n/m |
| CRMD CorMedix Inc compare | 3.0× |
| VALN Valneva SE Sponsored ADR compare | 59.7× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)